War Is Over. Give Peace a Chance (with apologies to the late John Lennon)

MANFRED HARTH and WARREN NIELSON

J Rheumatol 2009;36;2837-2838
http://www.jrheum.org/content/36/12/2837

1. Sign up for TOCs and other alerts
   http://www.jrheum.org/alerts

2. Information on Subscriptions
   http://jrheum.com/faq

3. Information on permissions/orders of reprints
   http://jrheum.com/reprints_permissions

*The Journal of Rheumatology* is a monthly international serial edited by Earl D. Silverman featuring research articles on clinical subjects from scientists working in rheumatology and related fields.
In his recent essay on fibromyalgia syndrome (FMS), entitled “Fibromyalgia Wars,” Wolfe paints a picture of this condition as one that epitomizes a conflict between practicing physicians, on the one hand, and an assortment of organized, powerful antagonists including academics, the pharmaceutical industry, patient support groups, lawyers, the Food and Drug Administration, the World Health Organisation, and the American College of Rheumatology. Casting oneself as the underdog is a good ploy for attracting sympathy and more easily enables the use of emotive rather than rational arguments. A “straw man” is erected and then attacked primarily using speculative concepts and ideas derived from a few medical historians.

In contrast to the controlling influence of a “pharmaco-academic complex” (p. 672) in FMS portrayed by Wolfe, our personal experience has been that an interest in FMS has typically been regarded by our academic colleagues with politely disguised condescension, if not outright pity. Support groups, at least in Canada, have been politically ineffective, and the pharmaceutical industry was, until quite recently, conspicuous by its absence. The pendulum may have swung somewhat in the past 3 or 4 years, but certainly not as widely as Wolfe would have it.

As far as we can discern, Wolfe’s arguments against FMS are as follows:

1. FMS is part of a continuum of pain and other distress and therefore should not be considered a separate entity.
2. The absence of “a specific pathological process”; 
3. The socially and emotionally deleterious effects of labeling; 
4. FMS is a “socially constructed illness”; 
5. The lack of progress in improving the symptoms of FMS.

We will briefly address each of these points:

FMS is part of a continuum of pain and other distress and therefore should not be considered a separate entity. Wolfe may well be part of a continuum of pain and distress labeled by some epidemiologists as “chronic widespread pain” (CWP). Many well accepted medical conditions fall along continua (e.g., hypertension, diabetes, obesity, and osteoporosis). Not all medical illness is dichotomous. In a continuum, normal becomes abnormal because a group of experts, using a statistical cutoff point and/or a consensus of opinion, has drawn a line in the sand. Moreover, artificial dichotomies are sometimes adopted. Why, for instance, must a patient meet 4 rather than 3 of the criteria for systemic lupus erythematosus (SLE) before being so labeled? It is unclear to us why being a continuum-based entity should serve as a rejection criterion for FMS but not other medical illnesses. We feel that the acceptability of FMS as a diagnostic entity should be based at least partly on its heuristic value. As efficacious treatments for FMS have been developed, the heuristic value of the diagnosis has only increased. We have shown, incidentally, that there are clinically, socially, and statistically significant differences between patients with CWP who meet the diagnostic criteria for FMS (those with ≥ 11 tender points) and those who have fewer than 11 tender points.

The absence of “a specific pathological process.” Are pathological processes really absent in FMS? What about abnormalities in fundamental magnetic resonance imaging, high levels of substance P in the cerebrospinal fluid, low levels of human growth hormone, abnormalities in the hypothalamic pituitary axis, abnormal norepinephrine blood levels at rest and on stimulation, and abnormal nociceptive flexion reflex responses? Not specific? Perhaps, but are rheumatoid factor and antinuclear antibody specific? At this point in our understanding of FMS it seems no longer correct to suggest that pathological processes are absent.

The socially and emotionally deleterious effects of labeling. Contrary to speculative claims of harm made cited by Wolfe (p. 676), the scientific evidence actually suggests the opposite: individuals are not made worse when a diagnostic label is applied and society may be much better off, if for no other reason than decreased medical expenditures.

FMS is a “socially constructed illness.” The argument of “socially constructed illness” is a potent weapon. One can always use it, even if the scientific facts argue otherwise. Like Freud’s psychoanalytic theory, also once popular despite lack of scientific evidence and testability, it cannot be proven or disproven. One example cited by Wolfe is Ivan Illich’s work on the medicalization of illness (p. 573). Illich popularized the concept of iatrogenic illness (e.g., drug-induced illness, postoperative side effects) and medicalization of normal life experiences (birth, death) where medical intervention can do more harm than good. As we have noted above, that is clearly not the case with FMS.

Another viewpoint is that, throughout the history of medicine, illnesses have often been attributed to social and psychological rather than biological causes. Poorly understood diseases have been attributed to the psyche when the pathophysiology was not understood. Indeed, some of us still remember how peptic ulcer was a classical psychosomatic condition (today it might have been classified by some as a Medically Unexplained Symptom). What a pity that H. pylori put an end to this cherished concept. At one time rheumatoid arthritis, inflammatory bowel disease, asthma, hypertension, and hyperthyroidism were all considered psychosomatic illnesses.

The lack of progress in improving the symptoms of FMS. There was a time within living memory when SLE was a sentence of death, and rheumatoid arthritis a largely untreatable condition. Unfortunately, we did not consider giving up on them. Some promising treatments for FM are emerging. Like many other medical treatments, they are far from perfect and will occasionally be misapplied. This suggests that physicians should be well informed and vigilant. We do not think that FMS should become the disease that “dares not speak its name.”

Unlike Wolfe, we do not view — nor do we wish to view — scientific discourse on FM as a war, declared or otherwise. The debate surrounding FMS has usually been spirited, sometimes heated. We hope it will not degenerate into a war. In that case, as we know only too well, the first casualty would be the truth.

We also feel that it is time to address an increasing concern. In contrast with the diagnostic label “fibromyalgia,” referring to it as a “socially constructed illness” implies that there is no physiological basis and, to many, that it is ipso facto psychological or fictitious. As is the case for other chronic pain problems and those diagnosed with mental illnesses, individuals with FMS are often the target of disparagement and derision. In our community, some family physicians will not take those who have FMS or other chronic pain conditions as patients. Despite the apparent benefits of diagnosis and the availability of treatments, many rheumatologists refuse to accept referrals of patients who are likely to have FMS. The “delegitimization” and “betrayal” that Wolfe notes (p. 671), often felt by patients as they interact with the medical system, isn’t imagined. Would we tell a patient with systemic sclerosis (SSc) as Wolfe suggests (p. 676) for patients with FMS: “Some doctors call your problems scleroderma. Scleroderma is a disease of long and short duration” (p. 676). We feel that it is time to put an end to this cherished concept.

We also feel that it is time to address the considerable concern that Wolfe has for FMS. Wolfe mentions, for instance, that “some doctors call your problems scleroderma. Scleroderma is a disease of long and short duration” (p. 676). We feel that it is time to put an end to this cherished concept.

We also feel that it is time to address the considerable concern that Wolfe has for FMS. Wolfe mentions, for instance, that “some doctors call your problems scleroderma. Scleroderma is a disease of long and short duration” (p. 676). We feel that it is time to put an end to this cherished concept.

We also feel that it is time to address the considerable concern that Wolfe has for FMS. Wolfe mentions, for instance, that “some doctors call your problems scleroderma. Scleroderma is a disease of long and short duration” (p. 676). We feel that it is time to put an end to this cherished concept.

We also feel that it is time to address the considerable concern that Wolfe has for FMS. Wolfe mentions, for instance, that “some doctors call your problems scleroderma. Scleroderma is a disease of long and short duration” (p. 676). We feel that it is time to put an end to this cherished concept.
medical condition (Axis III) and any concomitant psychiatric comorbidity on Axis I. In addition to the lack of scientific support for the diagnosis, it was recognized that assigning patients with pain problems to Axis I had been stigmatizing.

Is it not time to stop engaging in a “battle for symptom legitimacy,” and to use the tools we have available to improve the health and quality of life of patients with FMS?

MANFRED HARTH, MD, University of Western Ontario, Medicine (Rheumatology); WARREN NIELSON, PhD, St. Joseph’s Health Care, Rheumatology Day Programs, London, Ontario, Canada. Address correspondence to Dr. Nielson, warren.nielson@sjhc.london.on.ca or Dr. Harth, harth@aimhealthgroup.com

ACKNOWLEDGMENT
We thank Marilyn L. Hill for her helpful comments.

REFERENCES
12. Wallis C. The right (and wrong) way to treat pain. Hint: it takes more than a prescription pad to bring relief. Time 2005;166:46.

J Rheumatol 2009;36:12; doi:10.3899/jrheum.090508